Clindamycin Hydrochloride for Injection

Clindamycin hydrochloride.

The following infectious diseases caused by Gram-positive bacteria: 1. Tonsillitis, suppurative otitis media, sinusitis, etc. 2. Acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc. 3. Skin and soft tissue infections: furuncle, sore, abscess, cellulitis, trauma, burns and surgical infection, etc. 4. Urinary system infection: acute urethritis, acute pyelonephritis, prostatitis, etc. 5. Others: myelitis, sepsis, peritonitis and oral infection, etc. Various infectious diseases caused by anaerobic bacteria: 1. Empyema, muscle abscess, anaerobic pneumonia. 2. Skin and soft tissue infection, sepsis. 3. Intraperitoneal infection: peritonitis, intraperitoneal abscess. 4. Female pelvic and genital infections: endometritis, non-gonococcal fallopian tube and ovarian abscess.

Adults: deep intramuscular injection or intravenous drip. Moderate infection: 0.6~1.2g/day, divided into 2~3 times. Severe infection: 1.2~2.7g/day, divided into 2~3 times. Or as directed by a doctor. Children: intramuscular injection or intravenous drip. Moderate infection: 15~25mg/kg/day, divided into 2~3 times. Severe infection: 25~40mg/kg/day, divided into 2~3 times. Or as directed by a doctor. Intravenous drip: dilute 0.3g of this product with 100ml of normal saline or 5% glucose solution and drip intravenously for 30 minutes.

1 Local reaction: After intramuscular injection, slight pain may occasionally occur at the injection site. Long-term intravenous infusion should pay attention to the occurrence of phlebitis. 2 Gastrointestinal reactions: Occasionally, nausea, vomiting, abdominal pain and diarrhea may occur. 3 Allergic reactions: A small number of patients may develop drug-induced rashes. 4 There is basically no toxic reaction to the hematopoietic system. It may occasionally cause neutropenia, eosinophilia, thrombocytopenia, etc., which are generally mild and transient. 5 A small number of patients may experience transient alkaline phosphatase, mild elevation of serum transaminases and jaundice. 6 A very small number of patients may develop pseudomembranous colitis.

This product has cross-resistance with lincomycin and is contraindicated in patients with a history of allergy to this product or lincomycin.

1. This product can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when used in combination during or after surgery. Treatment with anti-basic esterase drugs or calcium salts is expected to be effective. 2. This product can cause pseudomembranous colitis with severe watery diarrhea during or even weeks after the course of treatment when used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay. Because it can delay the excretion of colonic endotoxins, leading to prolonged and aggravated diarrhea, this product should not be used in combination with antiperistaltic antidiarrheal drugs. When used in combination with antidiarrheal drugs containing white clay, the absorption of this product will be significantly reduced, so the two should not be taken at the same time, and a certain interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect and can enhance the effect of neuromuscular blocking drugs. The two should be avoided in combination. When this product is used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4 Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the binding of this product to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5 When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may add up to prolong respiratory depression or cause respiratory paralysis (apnea), so patients must be closely observed or monitored. 6 This product should not be added to infusions with complex components to avoid incompatibility.

Keep tightly closed.

0.5g (calculated based on C18H33ClN2O5 tablets)

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

• Founded in:

  2010-07-16

• Address:

  No. 6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone

• Tax NO.:

  914401015583834183

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view